Josh Jennings
Stock Analyst at Morgan Stanley
(2.66)
# 2,075
Out of 4,711 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $46.19 | +14.74% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $266.57 | +12.54% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $3.09 | +547.25% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $16.49 | +282.05% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.92 | +665.03% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $74.81 | -46.53% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $46.19
Upside: +14.74%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $266.57
Upside: +12.54%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $3.09
Upside: +547.25%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $16.49
Upside: +282.05%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.92
Upside: +665.03%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $74.81
Upside: -46.53%